COVID-19: Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus.
Date: March 19th, 2020
The National Institute on Drug Abuse (NIDA) has issued a Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19).
NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.
From the NOSI:
In order to rapidly improve our understanding of the risks, prevalence, and available control measures for 2019-nCoV in substance using or HIV-affected populations, NIDA is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:
- Research to determine whether substance use (especially smoking tobacco or marijuana, vaping, opioids and other drug use) is a risk factor for the onset and progression of COVID-19.
- Research on how HIV among persons who use substances may impact the onset and progression of COVID-19.
- Research to understand system-level responses to COVID-19 prevention and risk mitigation in secure settings such as prisons and jails, with a particular emphasis on detainees with substance use disorder (SUD).
- Interactions of COVID-19 treatment with SUD treatments, including medications for opioid use disorders.
- Strategies for integrating COVID-19 and other infectious disease screening, prevention, and treatment protocols with SUD treatment and other health services.
- Research to understand the respiratory effects of SARS-CoV-2 infection among individuals with substance use disorders (SUD); in particular those with nicotine, marijuana, opioid, and methamphetamine use disorders.
- Research to understand how the respiratory effects of COVID-19 influences the rate of opioid overdoses both in pain patients as well as patients with an opioid use disorders and also to assess how it influences the outcomes for naloxone interventions for overdose reversal.
- Research to develop therapeutic approaches for comorbid SARS-CoV-2 infection and SUDs.
- Research to evaluate drug-drug interaction of medications to treat SARS-CoV-2 and substances of abuse or medications to treat SUDs.
- Research to understand system- or organizational-level responses to identify, prevent, or mitigate the impact of COVID-19 in service settings that serve vulnerable populations, including people who are homeless or unstably housed.
- Research to understand and mitigate the impact of COVID-19 in methadone treatment programs and syringe exchange services.
- Research on how potential overcrowding of emergency departments and health services will impact the treatment of opioid overdoses and of opioid use disorder.
- Research using ongoing studies to understand the broad impacts of COVID-19 (e.g., school closures, food insecurity, anxiety, social isolation, family loss) on neurodevelopment, substance use, substance use disorders, and access to addiction treatment.
Further Reading: See the full text of NOT-DA-20-047